Dueñas-Garcia Omar Felipe, Sullivan Gina, Hall Cynthia D, Flynn Michael Kevin, OʼDell Katharine
From the UMass Memorial Medical Center, University of Massachusetts, Worcester, MA.
Female Pelvic Med Reconstr Surg. 2016 Mar-Apr;22(2):63-9. doi: 10.1097/SPV.0000000000000244.
The purpose of this systematic review was to evaluate and summarize pharmacological interventions evaluated in randomized clinical trials designed to prevent recurrent episodes of urinary tract infections (UTIs) in postmenopausal women.
Excerpta Medica dataBASE, Pubmed, Medline, and Cochrane Library were accessed to search for nonexperimental drugs evaluated in randomized clinical trials published in peer reviewed journals from January 1, 1970, to August 1, 2015, to reduce the number of recurrent UTIs in postmenopausal women.
A systematic search yielded 9 articles that met eligibility criteria. Five articles involved the use of systemic or vaginal estrogen therapy and the remainder used oral antibiotics, lactobacilli, or a combination of interventions. Antibiotics were the most efficacious therapy but with a higher incidence of systemic side effects. Oral lactobacillus was noninferior to sulfamethoxazole with trimethoprim with a safer profile in 1 small study. Vaginal estrogen appeared to be inferior to continuous oral antibiotic suppression; however, use of multiple formulations of both treatment options precludes meta-analysis. Oral estrogen use did not decrease UTI recurrence and resulted in local and systemic side effects in up to nearly 30% of the patients.
This review supports the use of antibiotic suppression, vaginal estrogen, and oral lactobacillus for prevention of recurrent UTIs in postmenopausal women. However, the overall dearth of data suggests that this is an important but understudied population. Because the effectiveness and safety of available treatments are not well understood, they should be used with caution in older populations, pending further study.
本系统评价旨在评估和总结在旨在预防绝经后妇女复发性尿路感染(UTI)的随机临床试验中所评估的药物干预措施。
检索荷兰医学文摘数据库(Excerpta Medica dataBASE)、PubMed、Medline和考克兰图书馆,以查找在1970年1月1日至2015年8月1日期间发表于同行评审期刊上的随机临床试验中所评估的非实验性药物,这些试验旨在减少绝经后妇女复发性UTI的次数。
系统检索得到9篇符合纳入标准的文章。5篇文章涉及全身或阴道雌激素治疗的使用,其余文章使用口服抗生素、乳酸杆菌或联合干预措施。抗生素是最有效的治疗方法,但全身副作用发生率较高。在1项小型研究中,口服乳酸杆菌与复方新诺明疗效相当,且安全性更高。阴道雌激素似乎不如持续口服抗生素抑制;然而,两种治疗方案使用多种制剂妨碍了荟萃分析。口服雌激素的使用并未降低UTI复发率,且在近30%的患者中导致局部和全身副作用。
本综述支持使用抗生素抑制、阴道雌激素和口服乳酸杆菌预防绝经后妇女复发性UTI。然而,总体数据匮乏表明这是一个重要但研究不足的人群。由于现有治疗方法的有效性和安全性尚未得到充分了解,在进一步研究之前,应谨慎用于老年人群。